Overview

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine the effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% (a single dose and 7 days of once daily [QD] dosing) on 2 aspects of aqueous humor (AqH) dynamics (episcleral venous pressure [EVP] and outflow facility) in participants with ocular hypertension (OHT).

Phase:

Phase 4

Details

Lead Sponsor:

Bausch & Lomb Incorporated

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions